Aditya Bardia, Mrinal M. Gounder, Jordi Rodón, Filip Janků, Martijn P. Lolkema, Joe Stephenson, Philippe L. Bédard, Martin Schüler, Cristiana Sessa, Patricia LoRusso, Michael Thomas, Heiko Maacke, Helen H. Evans, Yongjian Sun, Daniel Shao-Weng Tan,
Abstract Background This multicenter, open-label, phase Ib study investigated the safety and efficacy of binimetinib (MEK inhibitor) in combination with buparlisib (phosphatidylinositol 3-kinase [PI3K] inhibitor) in patients with advanced solid tumors with RAS/RAF alterations. Materials and Methods Eighty-nine patients were enrolled in the study. Eligible patients had advanced solid tumors with disease progression after standard therapy and/or for which no standard therapy existed. Evaluable disease ...
Tópico(s): Cancer Mechanisms and Therapy
2019 - AlphaMed Press | The Oncologist
Alison M. Schram, Kōichi Goto, Dong‐Wan Kim, Patricia Martín-Romano, Sai‐Hong Ignatius Ou, Grainne M. O’Kane, Eileen M. O’Reilly, Kumiko Umemoto, M. Duruisseaux, Cindy Neuzillet, Frans L. Opdam, Jordi Rodón, Misako Nagasaka, Benjamin A. Weinberg, Teresa Macarulla, Andrew K. Joe, Jim Ford, Viktoriya Stalbovskaya, Ernesto Wasserman, Alexander Drilon,
105 Background: NRG1 fusions are rare oncogenic drivers that have been identified in a variety of solid tumors. These proteins bind HER3, leading to HER2/HER3 heterodimerization and oncogenic transformation. Zenocutuzumab (MCLA-128; Zeno) is a Biclonics antibody that overcomes HER3 mediated NRG1 (or NRG1 fusion) signaling in tumor cells. Zeno docks on HER2, then binds to and blocks the NRG1 fusion-HER3 interaction and HER3 heterodimerization with HER2. Zeno is being evaluated in patients (pts) with ...
Tópico(s): Monoclonal and Polyclonal Antibodies Research
2022 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Alison M. Schram, Eileen M. O’Reilly, Grainne M. O’Kane, Kōichi Goto, Dong‐Wan Kim, Cindy Neuzillet, Patricia Martín-Romano, M. Duruisseaux, Misako Nagasaka, Jordi Rodón, Benjamin A. Weinberg, K. Umemoto, Sai‐Hong Ignatius Ou, Teresa Macarulla, Christelle de la Fouchardière, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Alexander Drilon,
3003 Background: NRG1 fusion proteins are oncogenic drivers in pancreas cancer and other solid tumors. They bind HER3, leading to HER2/HER3 heterodimerization and oncogenic transformation. The activity of zenocutuzumab (MCLA-128; zeno), a bispecific antibody targeting NRG1 fusion signaling in NRG1 fusion positive ( NRG1+) cancers, is being evaluated in the ongoing global multicenter phase 2 part of the eNRGy study and a global early access program (EAP). Methods: Enrolled patients (pts) have advanced ...
Tópico(s): HER2/EGFR in Cancer Research
2021 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Alison M. Schram, Teresa Macarulla, James M. Cleary, Cindy Neuzillet, Dirk Arnold, Kim A. Reiss, Tanios Bekaii‐Saab, Jordi Rodón, Kōichi Goto, Sun Young Rha, M. Duruisseaux, Natasha B. Leighl, Benjamin A. Weinberg, Mohammed Najeeb Al Hallak, Andrew K. Joe, S. Adeyemi, Ernesto Wasserman, K-J. Koeman, Alexander Drilon, Eileen M. O’Reilly,
NRG1 fusions are rare oncogenic drivers of PDAC and other solid tumours. These chimeric proteins bind HER3, leading to HER2/HER3 heterodimerization and oncogenic transformation. Zenocutuzumab (MCLA-128; Zeno) is a bispecific antibody that overcomes HER3 mediated NRG1 signalling in NRG1+ cancer. Zeno is being evaluated in the ongoing pivotal phase II eNRGy study and early access program (EAP). Updated NRG1+ PDAC data are presented.
Tópico(s): HER2/EGFR in Cancer Research
2023 - Elsevier BV | Annals of Oncology
Alison M. Schram, Kōichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque, Eileen M. O’Reilly, Sai‐Hong Ignatius Ou, Jordi Rodón, Sun Young Rha, Kazumi Nishino, M. Duruisseaux, Joon Oh Park, Cindy Neuzillet, Stephen V. Liu, Benjamin A. Weinberg, James M. Cleary, Emiliano Calvo, Kumiko Umemoto, Misako Nagasaka, Christoph Springfeld, Tanios Bekaii‐Saab, Grainne M. O’Kane, Frans L. Opdam, Kim A. Reiss, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Shola Adeyemi, Lokesh Jain, Shekeab Jauhari, Alexander Drilon,
Tópico(s): Pancreatic and Hepatic Oncology Research
2025 - Massachusetts Medical Society | New England Journal of Medicine
Enaksha Wickremsinhe, Christopher James,
... Liberal J, Hierro C, Ochoa De Olza M, Rodon J. Immuno-oncology: the third paradigm in early ... Jian, John F Kellie, Anita Lee, John Mehl, Joe Palandra, Haibo Qiu, Natasha Savoie, Diaa Shakleya, Ludovicus ...
Tópico(s): Cell Image Analysis Techniques
2021 - Future Science Ltd | Bioanalysis
Joe Y. Chang, Xinyan Xu, Girish S. Shroff, Nathan I Comeaux, Wei Li, Jordi Rodón, Daniel D. Karp, Ecaterina E. Dumbrava, Vivek Verma, Aileen B. Chen, James W. Welsh, David S. Hong,
BMS-986156 is an agonist of the glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) and promotes increased effector T-cell activation. Combined anti-GITR, anti-programmed death-1, anti-cytotoxic T-lymphocyte-associated protein 4 antibodies and radiotherapy improve tumor control in preclinical studies. Herein we describe the results of the safety and efficacy of BMS-986156+ipilimumab or nivolumab with/without stereotactic ablative radiotherapy (SABR) in patients with ...
Tópico(s): Advanced Radiotherapy Techniques
2024 - BMJ | Journal for ImmunoTherapy of Cancer